Nuage Therapeutics has been awarded a competitive EIT Health grant to advance its mission of ushering in a new wave of transformational precision therapies for aggressive cancers. 

Nuage Therapeutics has been awarded a competitive grant from EIT Health, which forms part of the European Institute of Innovation and Technology (EIT), to advance its mission of ushering in a new wave of transformational precision therapies for aggressive cancers. The funded project, Unlocking the Druggability of Disordered Transcription Factors to deliver Transformative New Therapies, will accelerate Nuage’s pioneering approach to drug discovery.  

The grant will enable Nuage to continue demonstrating that its novel technology can unlock the druggability of Intrinsically Disordered Proteins (IDPs), a class of proteins long considered “undruggable”. IDPs play a critical role in multiple diseases across different therapeutic areas, including oncology. Nuage has developed a proprietary set of tools that enables the reconstitution of IDPs in a transiently druggable form, making them amenable to small-molecule drug discovery.  

Nuage’s groundbreaking approach is initially being deployed to target transcription factors that are key to the growth of specific cancers. With this new funding, Nuage will continue advancing its innovative research, targeting oncogenic transcription factors that drive cancer progression while shutting down key disease pathways that have remained inaccessible to conventional drug discovery.